Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series - Takeaways - MDSpire

Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series

  • By

  • Sandra Susanibar-Adaniya

  • Benjamin A. Derman

  • Adam D. Cohen

  • Dan T. Vogl

  • Shambavi Richard

  • Adriana Rossi

  • Matthew J. Frigualt

  • Andrew J. Yee

  • Binod Dhakal

  • Noffar Bar

  • April 28, 2026

  • 0 min

Share

  • 1

    Immune effector cell-associated enterocolitis (IEC-EC) is a significant complication following BCMA-targeted CAR T-cell therapy for multiple myeloma.

  • 2

    The incidence of IEC-EC was estimated at 4.3%, with a median onset of diarrhea occurring 81 days post-CART infusion.

  • 3

    Treatment for IEC-EC was varied and often ineffective, with 58% of patients receiving corticosteroids and only one showing symptomatic improvement.

  • 4

    Mortality related to IEC-EC was high, with 37% of patients dying from complications such as infection or intestinal perforation.

  • 5

    The pathophysiology of IEC-EC likely involves dysregulated T-cell activity, resembling features of graft-versus-host disease and common variable immunodeficiency.

Original Source(s)

Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series

  • by Sandra Susanibar-Adaniya, Benjamin A. Derman, Adam D. Cohen, Dan T. Vogl, Shambavi Richard, Adriana Rossi, Matthew J. Frigualt, Andrew J. Yee, Binod Dhakal, Noffar Bar

  • April 28, 2026

Related Content

Editorial: Progress and Future Directions in Cellular Treatments for Leukemia and Myeloma

Prognostic nutritional index, but not NLR or PLR, is linked to survival in multiple myeloma

Advancing CAR-T therapy in multiple myeloma: a critical appraisal of CARTITUDE-4 and the path toward earlier lines